Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study.

Simple item page
dc.contributor.authorThamprajamchit, Sen_US
dc.contributor.authorChetchotisakd, Pen_US
dc.contributor.authorThinkhamrop, Ben_US
dc.date.accessioned2009-05-27T21:14:08Z
dc.date.available2009-05-27T21:14:08Z
dc.date.issued1998-04-12en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractA prospective randomized, double-blind, controlled study of cefoperazone/sulbactam (cefoperazone 25 mg/kg/day) + co-trimoxazole (trimethoprim 8 mg/kg/day) vs ceftazidime (100 mg/kg/day) + co-trimoxazole (trimethoprim 8 mg/kg/day) in the treatment of severe melioidosis was conducted at Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand, from July 1995 to September 1996. A total of 84 patients were enrolled in the study. Forty of them (48%) had culture-proven melioidosis and were randomly assigned to one of the two treatment groups, each group with 20 patients. Two cases (one in each treatment group) were excluded from the final analysis due to incomplete data. There was no significant difference in the mortality rate between the two groups-16 per cent (3/19) in the cefoperazone/sulbactam group vs 21 per cent (4/19) in the ceftazidime group (p > 0.05). Bacteriological responses of successfully treated patients were similar in both groups, and both treatment regimens were well tolerated. Cefoperazone/sulbactam + co-trimoxazole can therefore be used as an alternative treatment for severe melioidosis. However, to further support this conclusion, a study with a larger patient population is needed.en_US
dc.description.affiliationDepartment of Medicine, Faculty of Medicine, Khon Kaen University, Thailand.en_US
dc.identifier.citationThamprajamchit S, Chetchotisakd P, Thinkhamrop B. Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study. Journal of the Medical Association of Thailand. 1998 Apr; 81(4): 265-71en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/44434
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAdulten_US
dc.subject.meshAnti-Bacterial Agents --therapeutic useen_US
dc.subject.meshAnti-Infective Agents --therapeutic useen_US
dc.subject.meshCefoperazone --therapeutic useen_US
dc.subject.meshCeftazidime --therapeutic useen_US
dc.subject.meshChi-Square Distributionen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Therapy, Combination --therapeutic useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMelioidosis --drug therapyen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshStatistics, Nonparametricen_US
dc.subject.meshSulbactam --therapeutic useen_US
dc.subject.meshTrimethoprim-Sulfamethoxazole Combination --therapeutic useen_US
dc.titleCefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study.en_US
dc.typeClinical Trialen_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
dc.typeRandomized Controlled Trialen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand